Targeting multidrug resistance in cancer
- PMID: 16518375
- DOI: 10.1038/nrd1984
Targeting multidrug resistance in cancer
Abstract
Effective treatment of metastatic cancers usually requires the use of toxic chemotherapy. In most cases, multiple drugs are used, as resistance to single agents occurs almost universally. For this reason, elucidation of mechanisms that confer simultaneous resistance to different drugs with different targets and chemical structures - multidrug resistance - has been a major goal of cancer biologists during the past 35 years. Here, we review the most common of these mechanisms, one that relies on drug efflux from cancer cells mediated by ATP-binding cassette (ABC) transporters. We describe various approaches to combating multidrug-resistant cancer, including the development of drugs that engage, evade or exploit efflux by ABC transporters.
Similar articles
-
Mouse ATP-Binding Cassette (ABC) Transporters Conferring Multi-Drug Resistance.Anticancer Agents Med Chem. 2015;15(4):423-32. Anticancer Agents Med Chem. 2015. PMID: 25929575 Review.
-
ABC Transporters in the Development of Multidrug Resistance in Cancer Therapy.Curr Pharm Des. 2016;22(30):4705-4716. doi: 10.2174/1381612822666160302103646. Curr Pharm Des. 2016. PMID: 26932159 Review.
-
Relevance of multidrug resistance in the age of targeted therapy.Curr Opin Drug Discov Devel. 2009 Mar;12(2):246-52. Curr Opin Drug Discov Devel. 2009. PMID: 19333870 Review.
-
The emergence of drug transporter-mediated multidrug resistance to cancer chemotherapy.Mol Pharm. 2011 Dec 5;8(6):1996-2011. doi: 10.1021/mp200261n. Epub 2011 Jul 26. Mol Pharm. 2011. PMID: 21770407 Review.
-
Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer.Curr Opin Pharmacol. 2006 Aug;6(4):350-4. doi: 10.1016/j.coph.2006.01.009. Epub 2006 May 11. Curr Opin Pharmacol. 2006. PMID: 16690355 Review.
Cited by
-
Extracellular Vesicles in Chemoresistance.Subcell Biochem. 2021;97:211-245. doi: 10.1007/978-3-030-67171-6_9. Subcell Biochem. 2021. PMID: 33779919
-
A promising strategy for overcoming MDR in tumor by magnetic iron oxide nanoparticles co-loaded with daunorubicin and 5-bromotetrandrin.Int J Nanomedicine. 2011;6:2123-31. doi: 10.2147/IJN.S24309. Epub 2011 Sep 27. Int J Nanomedicine. 2011. PMID: 22114476 Free PMC article.
-
miR-135a/b modulate cisplatin resistance of human lung cancer cell line by targeting MCL1.Pathol Oncol Res. 2013 Oct;19(4):677-83. doi: 10.1007/s12253-013-9630-4. Epub 2013 May 3. Pathol Oncol Res. 2013. PMID: 23640248
-
Methuosis Inducer SGI-1027 Cooperates with Everolimus to Promote Apoptosis and Pyroptosis by Triggering Lysosomal Membrane Permeability in Renal Cancer.Adv Sci (Weinh). 2024 Oct;11(38):e2404693. doi: 10.1002/advs.202404693. Epub 2024 Aug 9. Adv Sci (Weinh). 2024. PMID: 39119834 Free PMC article.
-
Tackling breast cancer chemoresistance with nano-formulated siRNA.Gene Ther. 2016 Dec;23(12):821-828. doi: 10.1038/gt.2016.67. Epub 2016 Sep 20. Gene Ther. 2016. PMID: 27648580 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous